Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors

PURPOSE: This multicenter phase 2 study assessed the tolerability and efficacy of motesanib, an oral inhibitor of Kit, platelet-derived growth factor receptor (PDGFR), and vascular endothelial growth factor receptors (VEGFR), in patients with imatinib-resistant gastrointestinal stromal tumors (GIST)...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Benjamin, Robert S., Schöffski, Patrick, Hartmann, Jörg Thomas, Van Oosterom, Allan, Bui, Binh Nguyen, Duyster, Justus, Schuetze, Scott, Blay, Jean-Yves, Reichardt, Peter, Rosen, Lee S., Skubitz, Keith, McCoy, Sheryl, Sun, Yu-Nien, Stepan, Daniel E., Baker, Laurence
Format: Artigo
Jezik:Inglês
Izdano: Springer-Verlag 2010
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3123696/
https://ncbi.nlm.nih.gov/pubmed/20838998
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-010-1431-9
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items